These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17089440)

  • 1. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
    Hubbard RD; Wilsbacher JL
    ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
    [No Abstract]   [Full Text] [Related]  

  • 2. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
    Steiner L; Blum G; Friedmann Y; Levitzki A
    Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of selective, ATP-competitive inhibitors of Akt.
    Freeman-Cook KD; Autry C; Borzillo G; Gordon D; Barbacci-Tobin E; Bernardo V; Briere D; Clark T; Corbett M; Jakubczak J; Kakar S; Knauth E; Lippa B; Luzzio MJ; Mansour M; Martinelli G; Marx M; Nelson K; Pandit J; Rajamohan F; Robinson S; Subramanyam C; Wei L; Wythes M; Morris J
    J Med Chem; 2010 Jun; 53(12):4615-22. PubMed ID: 20481595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
    Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
    J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
    Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
    Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
    J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
    Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
    Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Rhodes N; Heerding DA; Duckett DR; Eberwein DJ; Knick VB; Lansing TJ; McConnell RT; Gilmer TM; Zhang SY; Robell K; Kahana JA; Geske RS; Kleymenova EV; Choudhry AE; Lai Z; Leber JD; Minthorn EA; Strum SL; Wood ER; Huang PS; Copeland RA; Kumar R
    Cancer Res; 2008 Apr; 68(7):2366-74. PubMed ID: 18381444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
    Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
    Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The involvement of phosphatidylinositol 3-kinase in gonadotropin-releasing hormone-induced gonadotropin alpha- and FSHbeta-subunit genes expression in clonal gonadotroph LbetaT2 cells.
    Mutiara S; Kanasaki H; Harada T; Oride A; Miyazaki K
    Mol Cell Endocrinol; 2008 Feb; 283(1-2):1-11. PubMed ID: 18206295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
    Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.